



Stop TB Partnership hosted by **UNOPS**


GDF's Pediatric DR-TB Initiative

Advancing from Successful Introduction to Scaling Up and Ensuring Sustainability


Pediatric Drug-Resistant Tuberculosis (DR-TB) medicines constitute a particularly fragile and low-demand market, posing significant challenges in the development and introduction of new formulations to the countries in need. Established in 2018, The Stop TB Partnership's Global Drug Facility's (GDF) Pediatric DR-TB Initiative has been dedicated to overcoming these obstacles and expediting the development, adoption, and scale-

up of child-friendly medicines and treatment regimens for DR-TB. Funded by the Government of Japan and United States Agency for International Development (USAID), the Initiative concluded in early 2024. During 2018-2023, GDF has successfully achieved its objective of introducing child-friendly formulations for all 11 oral medicines the World Health Organization recommends for the treatment of DR-TB in children.

Key Achievements



GDF delivered child-friendly formulations for DR-TB treatment to an est. **6,500 children**



Including an est. **2,000** treatment courses using child-friendly bedaquiline
(AVAILABLE SINCE JUNE 2020)

Including an est. **1,000** treatment courses using child-friendly delamanid
(AVAILABLE SINCE NOVEMBER 2021)

Sustainable funding has been secured for nearly all GDF-supported countries, ensuring uninterrupted access to these formulations in the future.

The Initiative adopted a multifaceted approach to achieve its objectives:



© Maggie Steber for Stop TB's GDF




© Ashley Gilbertson for Stop TB's GDF




This strategy involved prioritizing the development of new pediatric DR-TB formulations and employing pooled procurement and production planning to manage their supply and demand effectively.

Concurrently, the Initiative provided technical assistance to countries on pediatric DR-TB medicine quantification and supply planning, facilitated funding for their initial procurement, identified sources of sustainable financing for the future, and offered clinical support for their implementation.

A pivotal partner in GDF's efforts to enhance access to pediatric DR-TB medicines is the Sentinel Project, a network comprising pediatric DR-TB-focused clinicians, researchers, and caregivers.



A central piece of the advocacy campaign is the **15-minute documentary that received an honorable mention at the 2020 Webby Awards**. This accolade underscores the documentary's success in reaching a broader audience beyond those typically engaged in the TB field. To further expand its reach globally, the documentary has been subtitled in the six official UN languages plus Japanese. **You can watch the 15-minute documentary by scanning the QR code below.**



Scan the QR Code or [click here](#)



Additionally, to raise awareness about pediatric TB, Stop TB Partnership formed a new partnership with Hello Kitty in November 2020.



Scan the QR Code or [click here](#)

Jointly funded by:



From
the People of Japan

